NEW YORK, NY (October 28, 2009) – Schrödinger announced today that it has successfully designed an inhibitor for an undisclosed enzyme that fulfills the milestone criteria for a pre-clinical candidate in a research collaboration with its long-time client, Solvay Pharmaceuticals. Citing its consistent innovations in drug discovery software, Solvay in early 2008 chose Schrödinger as its global core software provider. Later in 2008, Solvay entered into a research alliance with Schrödinger. Frédéric Cren, Solvay's Executive Vice President, Research at Solvay Pharmaceuticals, states "This partnership is a perfect example of Solvay's new research strategy to accelerate internal and external programs by building alliances with carefully selected partners who are chosen for their abilities to bring innovative technologies to compound design."

Since the alliance's formation, Schrödinger and Solvay scientists have collaborated on two projects. The first included hit identification and subsequent hit-to-lead and lead optimization support for an undisclosed enzyme, which plays an important role in the pathophysiology of pulmonary hypertension. Using Schrödinger's in-silico virtual screening technology, the hit rate was dramatically improved over previous traditional HTS methods, and furthermore, the hits were potent and demonstrated superior selectivity against a second isoform of the enzyme.

In the second project, Schrödinger collaborated with Solvay's Medicinal Chemistry group to provide lead optimization support for an undisclosed enzyme program, with the challenging goal to discover new chemotypes fulfilling Solvay’s pre-clinical candidate criteria. Utilizing Schrödinger's suite of drug discovery tools, the initial compound to be synthesized was found to fulfill Solvay’s internal milestone criteria for pre-clinical candidates. Based on additional computational analyses, Schrödinger also proposed a new compound class that in early testing has shown great promise.

"We are very pleased that we were able to bring the full suite of our discovery tools to bear in the collaboration projects with Solvay." said Dr. Ramy Farid, Schrödinger's President, "These exciting results are further validation of our in-silico platform technology; we look forward to building on these successes as we forge ahead."

About Schrödinger

Schrödinger is a scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research. The Company provides products ranging from general molecular modeling programs to a full-featured suite of drug design software using both ligand- and structure-based methods. The predictive power of Schrödinger's software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might not be possible otherwise, which are enabled through the Company’s breakthroughs in the fields of quantum chemistry, molecular modeling, drug design, and protein structure determination. Schrödinger operates from locations in New York, Oregon, California, Germany, and the UK. For more information, please visit www.schrodinger.com .

About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion, and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

Contact:
Shi-Yi Liu
(503) 299-1150
Shi-Yi.Liu@schrodinger.com